Study S000067

Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07702461
Study type: OBSERVATIONAL
Status: RECRUITING
Enrollment: 300
Start: 2026-06-12
Primary completion: 2026-10
Lead sponsor: Ohio State University
Conditions: Obesity & Overweight; Diabetes (DM)
Interventions: DRUG:Glucagon-Like Peptide-1 Agonist (GLP-1)
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Change in Resistance Training Status Before Versus Since GLP-1 Receptor Agonist Initiation [Day 1]

Linked records (4)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0006611	A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Bikou A, Expert opinion on pharmacotherapy	2024	Systematic review	PMID 38629387 DOI	registry reference BACKGROUND:38629387
R0006708	Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Neeland IJ, Diabetes, obesity & metabolism	2024	Narrative review	PMID 38937282 DOI	registry reference BACKGROUND:38937282
R0015766	GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment. Mahase E, BMJ (Clinical research ed.)	2024	Commentary	PMID 39043396 DOI	registry reference BACKGROUND:39043396
R0007438	Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial. Sandsdal RM, Cardiovascular diabetology	2023	Randomized trial	PMID 36841762 DOI	registry reference BACKGROUND:36841762